WellSaid AI is the agentic AI platform that helps providers overcome the workforce constraints limiting cognitive care — enabling earlier diagnosis, earlier treatment, and access to reimbursable revenue that goes uncaptured today.
FDA-approved treatments for cognitive decline already exist. What's missing is the workforce to deliver them. Provider shortages and workflow inefficiencies delay diagnosis by up to two years — pushing patients past the window where treatment is most effective, and leaving health systems unable to capture the reimbursement that's already available to them today.
WellSaid AI identifies which patients need evaluation, guides them to diagnosis, triages them to the right specialist, and captures billable revenue at every step — while giving patients faster answers along the way.
Identify which patients need evaluation, triage them to the right specialist, and capture the diagnostic and monitoring revenue that goes uncaptured today — without requiring additional headcount.
Early screening and guided diagnosis — without inappropriate referrals or months sitting on a specialist's waitlist.
Each one addressing a distinct point in the clinical journey, brought together into a single platform your team adopts with one decision, not eight.
Replaces the paper-and-pencil MoCA with a more accurate, scalable, accessible screening layer — easy enough to run on every at-risk patient, not just the ones who speak up first.
A validated path to diagnosis that doesn't depend on a scarce neuropsych referral. Where a screener stops, we go further — clinical grade, comprehensive neuropsych diagnostic detail that delivers an answer in a day, not the year-plus wait for a specialist assessment.
Grounded in the same clinical interventions and research behind the U.S. POINTER study, we identify modifiable risk factors and coach the daily habits shown to delay or prevent progression — one program instead of scattered point tools.
For patients starting FDA-approved anti-amyloid therapies, clinical efficacy and safety monitoring is the missing layer holding treatment back today. As treatment moves to the home, this problem expands significantly.
Four capabilities, integrated into one platform — so providers make one decision, not eight, and it's easy to layer into existing workflows.
WellSaid AI's Baseline Cognitive Assessment is intuitive, easy to use, and produces a concise report I found genuinely helpful. Having practiced family medicine for nearly four decades, a tool like this would have been extremely useful. It will help primary care physicians identify subtle cognitive decline earlier and get the right patients referred to neurology sooner.
Grounded in NIH-funded scientific research, validated with real patients, and built on reimbursement structures that already exist.
Awarded 3 NIH Grants, 2 Additional Under Review · AARP AgeTech Collaborative · Amazon Alexa's Most Engaging Apps · Alzheimer's Association Recognition · Johns Hopkins AITC Partner · Long-Term Care Pitch Winner · Society on Aging Recognition
Tell us a bit about your organization and what you're hoping to solve for. We'll follow up within one business day to explore whether there's a fit.
partnerships@wellsaid.ai
(847) 441-4237
We respond to all inquiries within one business day.